- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01943786
RAS Switch in Patients With Metastatic RAS Native Colorectal Tumors Treated With 1st Line FOLFIRI-Cetuximab (BEAMING)
Prospective, Non-Interventional Study of K-ras Status Switch in K-ras Native Patients With Metastatic Colorectal Tumors Treated With FOLFIRI-Cetuximab as First-line Treatment
Adenocarcinoma of the colon and rectum is a common, serious disease and it is the second cause of death from cancer in Spain.
The prognosis of CRC depends to a great extent on its stage when diagnosed. Patients with advanced disease, who present up to 40% of all patients, have a poor prognosis. Although the application of modern chemotherapy and radiotherapy treatments obtains median survival periods of around 24 months, the proportion of patients with advanced disease who obtain a cure is low.
Systemic treatment of advanced CRC has changed considerably in the last ten years with the introduction of active drugs such as oxaliplatin, irinotecan, and capecitabine. The most commonly used first line regimens are 5-Fluorouracil-Leucovorin-Oxaliplatin (FOLFOX), Capecitabine-Oxaliplatin (XELOX), 5-Fluorouracil-Leucovorin-Irinotecan (FOLFIRI) and, to a lesser extent, Capecitabine-Irinotecan (XELIRI). Chemotherapy regimens are combined with different agents against therapeutic targets, three of which are effective in colon cancer: bevacizumab, which targets vascular endothelial growth factor (VEGF) and cetuximab or panitumumab, which target the epidermal growth factor receptor (EGFR).
The use of cetuximab and panitumumab is not recommended in patients with KRAS mutations and the combination of a VEGF and EGFR agents is not beneficial.
Two recent studies results have identified KRAS mutations as frequent drivers of acquired resistance to cetuximab and panitumumab in colorectal cancer patients. The conclusions indicate that the emergence of KRAS mutant clones can be detected non-invasively months before radiographic progression by a DNA Blood Test (Inostics´BEAMing Technology).
Centro Integral Oncológico Clara Campal (CIOCC) is aiming to undertake a pioneer project aimed at integrating the analysis of KRAS switch status by BEAMing Technology in patients with metastatic colorectal cancer, tumor KRAS wild-type and BEAMing wild-type treated with first line FOLFIRI-cetuximab
In naive chemotherapy tumor-KRAS wild-type metastatic colorectal cancer patients, who are BEAMing positive (KRAS mutated in blood) before treatment may have worse evolution in terms of PFS (progression Free Survival) and response rate than BEAMing negative (KRAS native in blood) patients.
To know the proportion of patients who are BEAMing positive (KRAS mutation can be detected in circulating extracellular DNA) at the beginning of treatment, could be of great importance for treatment efficacy.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Anticipated)
Contacts and Locations
Study Locations
-
-
-
Madrid, Spain, 28050
- Centro Integral Oncólógico Clara Campal (Madrid Norte Sanchinarro University Hospital)
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Diagnosis of stage IV colorectal adenocarcinoma.
- Patient ≥ 18 years of age.
- ECOG PS 0-1
- Life expectancy ≥ 6 months
- Candidate for first-line systemic chemotherapy according to regular clinical practice.
- Measurable disease.
- Wild-type KRAS
- Signed informed consent form.
Exclusion Criteria:
- Patient who has received prior chemotherapy for metastatic CRC, except for adjuvant treatment completed at least six months before entering study.
- Patient in whom there is a contraindication for the use of any of the drugs used in first-line treatment of colorectal cancer: 5-fluorouracil,, irinotecan or cetuximab
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
FOLFIRI + Cetuximab
Patients with advanced colorectal cancer and wild-type KRAS will receive FOLFIRI + Cetuximab according to regular clinical practice
|
Patients will receive study treatment (FOLFIRI + Cetuximab) according to regular clinical practice
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
To estimate the proportion of patients with advanced colorectal cancer in whom KRAS mutation can be detected in circulating extracellular DNA
Time Frame: Baseline
|
Baseline
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
To estimate the proportion of patients with metastatic colorectal cancer who switch from BEAMing negative to BEAMing positive while being treated with first line FOLFIRI-Cetuximab
Time Frame: At 4 months and every eight weeks until disease progression up to 12 months
|
At 4 months and every eight weeks until disease progression up to 12 months
|
|
To estimate the response rate, in biopsy-proven K-ras wild-type patients according to KRAS status in circulating extracellular DNA.
Time Frame: Every eight weeks until disease progression up to 12 months
|
Every eight weeks until disease progression up to 12 months
|
|
Disease control rate according to KRAS status in circulating extracellular DNA.
Time Frame: Every eight weeks until disease progression up to 12 months
|
Every eight weeks until disease progression up to 12 months
|
|
Complete response rate according to KRAS status in circulating extracellular DNA.
Time Frame: Every eight weeks until disease progression up to 12 months
|
Every eight weeks until disease progression up to 12 months
|
|
Duration of response according to KRAS status in circulating extracellular DNA.
Time Frame: Every eight weeks until disease progression, up to 12 months
|
From date of first documented response until de date of first documented progression or date of death from any cause, whichever came first, assessed up to 12 months
|
Every eight weeks until disease progression, up to 12 months
|
Early tumor shrinkage
Time Frame: At 4 months
|
At 4 months
|
|
Number of each adverse event per cycle
Time Frame: Every 2 weeks, until end of treatment, up to 12 months
|
Every 2 weeks, until end of treatment, up to 12 months
|
Collaborators and Investigators
Investigators
- Principal Investigator: Antonio Cubillo, Doctor, Madrid Norte Sanchinarro University Hospital
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- BEAMING
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Colorectal Cancer Metastatic
-
Mayo ClinicCompletedMetastatic Colorectal Adenocarcinoma | Metastatic Colon Adenocarcinoma | Metastatic Colorectal Carcinoma | Metastatic Rectal Adenocarcinoma | Stage IV Colorectal Cancer AJCC v8 | Stage IVA Colorectal Cancer AJCC v8 | Stage IVB Colorectal Cancer AJCC v8 | Stage IVC Colorectal Cancer AJCC v8 | Metastatic... and other conditionsUnited States
-
Emory UniversityBristol-Myers Squibb; National Cancer Institute (NCI); National Institutes of...Active, not recruitingColorectal Cancer Metastatic | Colorectal Adenocarcinoma | Stage IV Colorectal Cancer | Stage IVA Colorectal Cancer | Stage IVB Colorectal Cancer | Refractory Colorectal Carcinoma | Metastatic Microsatellite Stable Colorectal Carcinoma | Stage IVC Colorectal CancerUnited States
-
Array Biopharma, now a wholly owned subsidiary...CompletedMetastatic Colorectal Cancer | Advanced Solid Tumors | Advanced or Metastatic Biliary CancerUnited States
-
Hutchison Medipharma LimitedActive, not recruitingMetastatic Colorectal Cancer | Metastatic Colon CancerUnited States, Spain, Japan, Australia, Austria, Belgium, Czechia, Estonia, France, Germany, Hungary, Italy, Poland, United Kingdom
-
Zhejiang Cancer HospitalNot yet recruitingMetastatic Colorectal Cancer | Metastatic Colorectal Adenocarcinoma | CRCChina
-
Academic and Community Cancer Research UnitedNational Cancer Institute (NCI)Active, not recruitingMetastatic Pancreatic Adenocarcinoma | Stage IV Pancreatic Cancer AJCC v6 and v7 | Stage IV Colorectal Cancer AJCC v7 | Stage IVA Colorectal Cancer AJCC v7 | Stage IVB Colorectal Cancer AJCC v7 | Metastatic Gastroesophageal Junction Adenocarcinoma | Metastatic Colorectal Carcinoma | Metastatic Malignant... and other conditionsUnited States
-
Dana-Farber Cancer InstituteAmerican Cancer Society, Inc.Not yet recruitingMetastatic Colorectal Cancer | Colorectal Cancer | Metastatic Colon CancerUnited States
-
AmgenCompletedCancer | Metastatic Colorectal Cancer | Colorectal Cancer | Rectal Cancer | Metastatic Cancer | Colon Cancer
-
AmgenCompletedCancer | Metastatic Colorectal Cancer | Colorectal Cancer | Rectal Cancer | Metastatic Cancer | Colon Cancer | Oncology
-
Symphogen A/STerminatedCarcinoma | Metastatic Colorectal Cancer | Colorectal Cancer MetastaticUnited States, Spain, Germany, Italy
Clinical Trials on FOLFIRI + Cetuximab
-
Hoffmann-La RocheCompletedColorectal CancerBelgium, Spain, France, Germany, United States, United Kingdom, Italy, Australia, Poland
-
UNICANCERCompletedMetastatic Colorectal CancerFrance
-
Arbeitsgemeinschaft medikamentoese TumortherapieMerck Sharp & Dohme LLCCompleted
-
National Cancer Institute, NaplesRecruitingColorectal Cancer | ADCCItaly
-
Henan Cancer HospitalCompletedWild-type KRAS,NRAS and BRAF V600E Metastatic Colorectal Cancer
-
Shanghai General Hospital, Shanghai Jiao Tong University...UnknownColorectal Cancer Metastatic
-
Istituto Scientifico Romagnolo per lo Studio e...CompletedMetastatic Colorectal CancerItaly
-
Universitaire Ziekenhuizen KU LeuvenMerck KGaA, Darmstadt, GermanyCompletedColorectal CancerSpain, France, Belgium, Hungary, Austria
-
SFJ Pharmaceuticals X, LTD.Merck KGaA, Darmstadt, Germany; AIO-Studien-gGmbH; Academic and Community Cancer... and other collaboratorsWithdrawn
-
Dr. Carl SchimanskiUnknown